MANKINDPharmaceuticals
Mankind Pharma Ltd — Profit & Loss Statement
₹2005.80
+0.73%
Mankind Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Normalized Income | 1.74K Cr | 1.82K Cr | 1.26K Cr | 1.36K Cr |
| Net Income From Continuing And Discontinued Operation | 1.99K Cr | 1.91K Cr | 1.28K Cr | 1.43K Cr |
| Total Expenses | 9.69K Cr | 8.02K Cr | 7.11K Cr | 5.90K Cr |
| Rent Expense Supplemental | 25.68 Cr | 21.68 Cr | 20.43 Cr | 21.26 Cr |
| Diluted Average Shares | 40.47 Cr | 40.12 Cr | 40.06 Cr | 40.06 Cr |
| Basic Average Shares | 40.40 Cr | 40.06 Cr | 40.06 Cr | 40.06 Cr |
| Diluted EPS | 49.20 | 47.68 | 32.00 | 35.78 |
| Basic EPS | 49.28 | 47.75 | 32.00 | 35.78 |
| Diluted NI Availto Com Stockholders | 1.99K Cr | 1.91K Cr | 1.28K Cr | 1.43K Cr |
| Net Income Common Stockholders | 1.99K Cr | 1.91K Cr | 1.28K Cr | 1.43K Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 1.99K Cr | 1.91K Cr | 1.28K Cr | 1.43K Cr |
| Minority Interests | -20.16 Cr | -28.87 Cr | -27.82 Cr | -19.48 Cr |
| Net Income Including Noncontrolling Interests | 2.01K Cr | 1.94K Cr | 1.31K Cr | 1.45K Cr |
| Net Income Discontinuous Operations | 4.53 Cr | 0.98 Cr | — | — |
| Net Income Continuous Operations | 2.01K Cr | 1.94K Cr | 1.31K Cr | 1.45K Cr |
| Tax Provision | 509.74 Cr | 457.15 Cr | 361.56 Cr | 521.64 Cr |
| Pretax Income | 2.52K Cr | 2.40K Cr | 1.67K Cr | 1.97K Cr |
| Other Non Operating Income Expenses | 19.61 Cr | 12.35 Cr | 16.52 Cr | 14.67 Cr |
| Special Income Charges | 149.54 Cr | -16.23 Cr | -14.16 Cr | 12.45 Cr |
| Other Special Charges | -159.56 Cr | -1.55 Cr | -5.97 Cr | 2.39 Cr |
| Write Off | 5.67 Cr | 13.09 Cr | 15.43 Cr | -14.83 Cr |
| Impairment Of Capital Assets | 4.35 Cr | 4.69 Cr | 4.71 Cr | 0.00 |
| Net Non Operating Interest Income Expense | -364.04 Cr | 5.37 Cr | -33.00 Cr | -46.88 Cr |
| Total Other Finance Cost | 11.06 Cr | 6.42 Cr | 5.49 Cr | 4.02 Cr |
| Interest Expense Non Operating | 420.89 Cr | 27.82 Cr | 40.27 Cr | 55.78 Cr |
| Interest Income Non Operating | 67.91 Cr | 39.61 Cr | 12.76 Cr | 12.92 Cr |
| Operating Income | 2.52K Cr | 2.24K Cr | 1.64K Cr | 1.88K Cr |
| Operating Expense | 6.12K Cr | 4.76K Cr | 4.15K Cr | 3.43K Cr |
| Other Operating Expenses | 1.37K Cr | 1.07K Cr | 1.20K Cr | 958.58 Cr |
| Depreciation And Amortization In Income Statement | 621.22 Cr | 378.42 Cr | 325.92 Cr | 166.62 Cr |
| Amortization | 362.29 Cr | 162.38 Cr | 158.83 Cr | 25.22 Cr |
| Depreciation Income Statement | 258.93 Cr | 216.04 Cr | 167.08 Cr | 141.40 Cr |
| Selling General And Administration | 1.38K Cr | 984.98 Cr | 669.06 Cr | 658.58 Cr |
| Selling And Marketing Expense | 931.63 Cr | 725.89 Cr | 457.61 Cr | 533.89 Cr |
| General And Administrative Expense | 448.76 Cr | 259.09 Cr | 211.45 Cr | 124.69 Cr |
| Rent And Landing Fees | 25.68 Cr | 21.68 Cr | 20.43 Cr | 21.26 Cr |
| Gross Profit | 8.64K Cr | 7.00K Cr | 5.79K Cr | 5.31K Cr |
| Cost Of Revenue | 3.57K Cr | 3.26K Cr | 2.96K Cr | 2.47K Cr |
| Total Revenue | 12.21K Cr | 10.26K Cr | 8.75K Cr | 7.78K Cr |
| Operating Revenue | 12.21K Cr | 10.26K Cr | 8.75K Cr | 7.78K Cr |
| Tax Effect Of Unusual Items | 63.35 Cr | 22.37 Cr | 5.03 Cr | 26.39 Cr |
| Tax Rate For Calcs | 0.20 | 0.19 | 0.22 | 0.26 |
| Normalized EBITDA | 3.25K Cr | 2.71K Cr | 2.01K Cr | 2.10K Cr |
| Total Unusual Items | 310.38 Cr | 117.30 Cr | 23.27 Cr | 99.88 Cr |
| Total Unusual Items Excluding Goodwill | 310.38 Cr | 117.30 Cr | 23.27 Cr | 99.88 Cr |
| Net Income From Continuing Operation Net Minority Interest | 1.99K Cr | 1.91K Cr | 1.28K Cr | 1.43K Cr |
| Reconciled Depreciation | 621.22 Cr | 398.25 Cr | 325.92 Cr | 166.62 Cr |
| Reconciled Cost Of Revenue | 3.57K Cr | 3.26K Cr | 2.96K Cr | 2.47K Cr |
| EBITDA | 3.56K Cr | 2.82K Cr | 2.04K Cr | 2.20K Cr |
| EBIT | 2.94K Cr | 2.43K Cr | 1.71K Cr | 2.03K Cr |
| Net Interest Income | -364.04 Cr | 5.37 Cr | -33.00 Cr | -46.88 Cr |
| Interest Expense | 420.89 Cr | 27.82 Cr | 40.27 Cr | 55.78 Cr |
| Interest Income | 67.91 Cr | 39.61 Cr | 12.76 Cr | 12.92 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mankind Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.